UnknownPhase 2/3

Place of 68Ga-PSMA-11 PET-CT in the Therapeutic Decision at the End of the Initial Staging for High Risk Prostate Cancer Patients

France33 participantsStarted 2018-01-02

Plain-language summary

Several studies have shown a great potential of 68Ga-PSMA PET in high risk prostate cancers patients and a high detection rate than 18F-Choline PET. The primary aim of this study is to evaluate the difference of management intent, after the inital staging of high risk prostate cancer patients, with 68Ga-PSMA-11 PET-CT results in comparison of 18F-Choline PET-CT results.

Who can participate

Age range18 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * high risk prostate cancer patients with initial tests : CT, bone scintigraphy and 18F-Choline Exclusion Criteria: * contraindication of 68Ga-PSMA PET-CT

What they're measuring

percentage of modification of management intent

Timeframe: 1 month

Trial details

NCT IDNCT03344822

SponsorCentral Hospital, Nancy, France

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2018-12-31

View on ClinicalTrials.gov More Prostate Cancer trials